Gentlemen & Women, as I always say, invest wisely, smartly and do your DD before buying. I like finding undervalued companies. I have done my research/DD and I really couldnt pass this one up, 'GLOB', CHARTS/ TECHNICALS/VOLUME indicate and show that this will be rallying from HERE ON OUT. They have a GREAT WEBSITE, GREAT PROFITABILITY, CANT DOUBT THIS COMPANY's POTENTIAL. Ok what got me hooked and see this as long term, was two simple HUGE statements made: "New RFID Product is Estimated to be a $1 Billion 'Green Field' Market Opportunity Internationally and is Expected to Generate Significant Revenues and Profits" & "The product is currently not for sale in the U.S., but is being sold in Europe. Global Med intends to apply for FDA clearance of the product in the near future." THOSE two sentences has made me a believer and i'm in it especially when they apply for FDA clearance. QUICK LOOK: With a possible Billion $ product and also breaking into US in the future, a small 36MIL Outstanding amount of shares, watch the 52 week high of $1.39 be shattered! I repeat shattered! *Financial Strong*: STRONG BALANCE SHEET+CASH FLOW+PROFITABILITY-HUGE FUTURE GROWTH POTENTIAL, here are some highlights of their 1st half ending June 30th, 2009: -First Half Revenues are Record High-First Half and Q2 Revenues Rose 74% and 66%, Respectively-Recurring Revenues Climb 20% -Global Med's record revenues of $16.418 million for the first half of 2009 represent an increase of $6.980 million or 74% over the $9.438 million recorded for the first half of 2008. In the first half of 2009, operating income improved to $1.678 million from $958 thousand during the first half of last year. The Company's net income for the first half of 2009 was $593 thousand, or $0.02 per basic common share outstanding, versus $512 thousand, or $0.02 per basic common share outstanding, for the first half of 2008. -Global Med's revenues of $8.059 million for the second quarter of 2009 represent an increase of $3.214 million or 66% over the $4.845 million recorded for the comparable 2008 period. In the second quarter of 2009, operating income improved to $621 thousand from $333 thousand during the comparable 2008 period. The Company's net income for the second quarter of 2009 increased 79% to $272 thousand, or $0.01 per basic common share outstanding, from $152 thousand, or $0.01 per basic common share outstanding, for the comparable 2008 period. -Global Med's cash flow from operations for the first half of 2009 was $3.891 million, a more than four-fold increase over the $887 thousand recorded for the first half of 2008. Recurring annual maintenance revenues for the quarter were running at an annualized rate of over $16.7 million. Based on the backlog as of June 30, 2009, the Company's annual recurring revenues, when all contracted customer sites are implemented, will be nearly $18.0 million, an increase of 20% over 2008. The Company's backlog of unrecognized software license fees and implementation fees as of June 30, 2009 was approximately $8.8 million, an increase of 59% over 2008. With this said, LET THE RALLY BEGIN.... My DD on recent news and they report a steady stream every week: ***9-17-09*** Global Med Technologies, Inc.'s CEO to Make Major New Product Announcement the Morning of the LDV Investor Conference and Will Demo the Product on Wednesday, September 23, 2009 Global Med Technologies ((R)), Inc. ("Global Med" or the "Company") (OTC Bulletin Board: GLOB), an international healthcare information technology company, today announced that Michael I. Ruxin, M.D., Global Med's Chairman and CEO, will make a major new product announcement the morning of the LDV Growth & Value Equity Conference which will be held at The Embassy Suites Boca Raton Hotel, Boca Raton, Florida. Dr. Ruxin will also demo the breakthrough product at the conference. "====The breakthrough medical product announcement will be concerning an innovative, European RFID medical device, that has just come on the market, and that has little competition with older medical device technologies that currently exist in the same area. Market penetration of these older medical devices is less than 10% in the U.S. market and has minimal penetration in international markets. The main reasons for the small market penetration globally are the high cost of these older medical devices, lengthy staff education needed to implement, and overall difficulty of use. Global Med's new RFID product will overcome all three of these concerns. The product is currently not for sale in the U.S., but is being sold in Europe. Global Med intends to apply for FDA clearance of the product in the near future.====" *9-15-09* Global Med Technologies((R)), Inc. ("Global Med" or the "Company") (OTC Bulletin Board: GLOB), an international e-Health, medical information technology company, today announced that its Inlog subsidiary has licensed its EdgeCell Cellular Therapy Software and EdgeLab/HLA Laboratory Information Management Software for Human Leukocyte Antigen matching (marketed as "Labo Serveur" in France) to the Hema-Quebec in Quebec, Canada Hema-Quebec will use EdgeCell in its Stem Cell Laboratory and Public Cord Blood Bank. EdgeCell is a state- of-the-art Cellular Therapy software solution for hospitals, surgery centers and health care facilities. EdgeCell fully tracks the procurement process including the medical history questionnaire, all required testing including specimen reception and infectious disease testing, product preparation, packaging, labeling and storage, as well as crossmatching and distribution. EdgeCell incorporates an extensive list of safety features along with full traceability and generation of regulatory documentation. *9-10-09* Global Med Technologies((R)), Inc. ("Global Med" or the "Company") (OTC Bulletin Board: GLOB), an international e-Health, medical information technology company, today announced that its Wyndgate Technologies division has licensed and deployed its SafeTrace Tx((R)) transfusion management software to Schuylkill Health of Pottsville, Pennsylvania. Schuylkill is also using the services of Global Med's PeopleMed((R)) subsidiary to validate the systems before go-live. Terms of the agreement were not disclosed. About Global Med Technologies((R)), Inc. Global Med Technologies, Inc. is an international healthcare information technology company which develops regulated and non- regulated products and services for the healthcare industry. As a leading provider of blood and laboratory systems and services, Global Med's products are deployed in 20 countries and serve over 2,100 transfusion centers, blood banks and laboratory sites. Global Med's domestic companies are Wyndgate Technologies((R)), a leader in software products and services for donor centers and hospital transfusion services; eDonor((R)), which offers web-based donor relationship management systems; and PeopleMed((TM)), Inc., which implements cost-effective software validation, consulting and compliance solutions to hospitals and donor centers. Global Med's European subsidiary, Inlog, SA, is a leading developer of *donor center and *transfusion management systems as well as cellular therapy software, *laboratory information systems and quality assurance medical software systems internationally. For more information about Global Med's products and services, please call 800-996-3428 or visit globalmedtech.com COME DOUBT THIS NOW on the DD!!
$0.0 (09/18/09)
